1. Home
  2. CINGW vs NWS Comparison

CINGW vs NWS Comparison

Compare CINGW & NWS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CINGW
  • NWS
  • Stock Information
  • Founded
  • CINGW N/A
  • NWS 2012
  • Country
  • CINGW United States
  • NWS United States
  • Employees
  • CINGW 13
  • NWS N/A
  • Industry
  • CINGW Biotechnology: Pharmaceutical Preparations
  • NWS Newspapers/Magazines
  • Sector
  • CINGW Health Care
  • NWS Consumer Discretionary
  • Exchange
  • CINGW Nasdaq
  • NWS Nasdaq
  • Market Cap
  • CINGW N/A
  • NWS N/A
  • IPO Year
  • CINGW 2021
  • NWS N/A
  • Fundamental
  • Price
  • CINGW $0.05
  • NWS $32.79
  • Analyst Decision
  • CINGW
  • NWS Strong Buy
  • Analyst Count
  • CINGW 0
  • NWS 4
  • Target Price
  • CINGW N/A
  • NWS $38.67
  • AVG Volume (30 Days)
  • CINGW N/A
  • NWS 879.0K
  • Earning Date
  • CINGW N/A
  • NWS 11-07-2024
  • Dividend Yield
  • CINGW N/A
  • NWS 0.61%
  • EPS Growth
  • CINGW N/A
  • NWS 158.28
  • EPS
  • CINGW N/A
  • NWS 0.62
  • Revenue
  • CINGW N/A
  • NWS $10,163,000,000.00
  • Revenue This Year
  • CINGW N/A
  • NWS $5.36
  • Revenue Next Year
  • CINGW N/A
  • NWS $3.54
  • P/E Ratio
  • CINGW N/A
  • NWS $48.64
  • Revenue Growth
  • CINGW N/A
  • NWS 2.66
  • 52 Week Low
  • CINGW N/A
  • NWS $22.21
  • 52 Week High
  • CINGW N/A
  • NWS $32.87
  • Technical
  • Relative Strength Index (RSI)
  • CINGW N/A
  • NWS 72.60
  • Support Level
  • CINGW N/A
  • NWS $31.68
  • Resistance Level
  • CINGW N/A
  • NWS $32.45
  • Average True Range (ATR)
  • CINGW 0.00
  • NWS 0.61
  • MACD
  • CINGW 0.00
  • NWS -0.05
  • Stochastic Oscillator
  • CINGW 0.00
  • NWS 96.45

About CINGW Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: